Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 4Not yet recruiting 3Active not recruiting 3Withdrawn 1Terminated 1Suspended 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 2Thoracic 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 1Leukemia, Plasma Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 64Magnetic Resonance Spectroscopy 44Carboplatin 34Cyclophosphamide 31Gemcitabine 29Biopsy 28Cisplatin 27Radiotherapy 26pembrolizumab 25Bevacizumab 25Paclitaxel 23Standard of Care 22Oxaliplatin 22Drug Therapy 22venetoclax 21Nivolumab 21Capecitabine 21fludarabine 20Injections 20Interviews as Topic 18Radiosurgery 16Dexamethasone 16Blood Specimen Collection 16Azacitidine 16toripalimab 15tislelizumab 14cemiplimab 13anlotinib 13Irinotecan 13Pemetrexed 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Hyaluronoglucosaminidase × 90 days × Clear all
NCT07605416 2026-05-26

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
74 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell

NCT06948084 2026-05-13

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
80 enrolled
Plasma cell

Multiple Myeloma

NCT07388524 2026-05-13

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

National Cancer Institute (NCI)

Phase 3 Not yet recruiting
336 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡